JAZZ vs VIVS · P/E 1988, rev $2.28B vs P/E 0.7, rev $131.0K
Jazz Pharmaceuticals PLC (JAZZ) versus VivoSim Labs, Inc. (VIVS) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
VivoSim Labs, Inc. (VIVS) is a biotechnology company listed on NASDAQ.
Latest reported JAZZ revenue for 2026-06-30 was $2.28B. Net income was $485.9M. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported VIVS revenue for 2026-03-31 was $131.0K. Net income was -$13.8M. Revenue was down 9.0% from 2025-03-31 to 2026-03-31. VIVS currently screens at market cap $3.5M and trailing P/E 0.7.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. VIVS currently screens at market cap $3.5M and trailing P/E 0.7.
Not investment advice. Open the JAZZ and VIVS stock pages for the full models.
Not investment advice.